RUTHERFORD, N.J. and RALEIGH, N.C., Dec. 10, 2014 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc . (Nasdaq: CGIX ) ("CGI" or "the Company"), an emerging leader in DNA-based cancer diagnostics, announced today that Rob Fannon has joined the company as vice president of operations in the Raleigh/Research Triangle Park (RTP), North Carolina location. Fannon, previously with Roche Molecular's BioSpecimen Management division, brings more than 10 years of operations, client management, molecular test and panel development, and biorepository management experience to CGI.
"Mr. Fannon brings CGI tremendous experience in molecular services, oncology therapeutic development, and laboratory operations. He will be a significant asset to the company and to our clients," said Panna Sharma, CEO of Cancer Genetics.
At Roche Molecular Systems, Fannon oversaw biospecimen acquisition, panel production, project management, and client relations. Prior to his tenure at Roche, Fannon served as clinical operations manager at BioServe Biotechnologies, Ltd. in Beltsville, MD, where he was responsible for sales, business development, and client relations. From 2006 to 2010, Fannon served as an editor and analyst at Stansberry and Associates Investment Research, where he established an investment advisory publication focused on investment opportunities in publicly-traded biotech, life science, and healthcare companies. Fannon also spent two years as a business development associate at the Johns Hopkins Bloomberg School of Public Health, where he assessed intellectual property opportunities and sought licensing opportunities for research with provisional patent coverage.
"I am excited to join the Cancer Genetics team and look forward to the challenges and opportunities of the new role," said Fannon. "As I step into this new position, I will work towards improving our genomic offering in order to meet the growing needs of our clinical trial customers. The entire RTP operation will be focused on further differentiating CGI as a global leader in the personalization of cancer care."
Mr. Fannon received his B.S. from East Carolina University and holds a Master of Public Health (MPH), and a Master of Business Administration (MBA) from Johns Hopkins University in Baltimore, MD.
About Cancer Genetics
Cancer Genetics Inc. is an emerging leader in DNA-based cancer diagnostics, servicing some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers . We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals, as well as biopharma and biotech companies. Our state-of-the-art reference labs are focused entirely on maintaining clinical excellence and are both CLIA certified and CAP accredited and have licensure from several states including New York State. We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute.
For more information, please visit or follow us:
Internet: http://www.cancergenetics.com
Twitter: @Cancer_Genetics
Facebook: www.facebook.com/CancerGenetics
Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that the transaction will not close or, if it closes, will not realize the currently anticipated benefits, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Company's Form 10-K for the year ended December 31, 2013 and 10-Q for the quarter ended September 30, 2014 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.
Media Relations Paul Kuntz RedChip Companies, Inc. 800-733-2447, ext. 105 Investor Relations Michael Rice LifeSci Advisors, LLC 646-597-6997
